

## DAFTAR PUSTAKA

- Barzilay, J. I., Kronmal, R. A., Gottdiener, J. S., Smith, N. L., Burke, G. L., Tracy, R., Savage, P. J., & Carlson, M. (2004). The association of fasting glucose levels with congestive heart failure in diabetic adults  $\geq 65$  years: The Cardiovascular Health Study. *Journal of the American College of Cardiology*, 43(12), 2236–2241. <https://doi.org/10.1016/j.jacc.2003.10.074>
- bin Rakhis, S. A., AlDuwayhis, N. M., Aleid, N., AlBarrak, A. N., & Aloraini, A. A. (2022). Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review. *Cureus*. <https://doi.org/10.7759/cureus.26180>
- Bonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., & Beltrami, M. (2024). Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease. *Biomedicines*, 12(5). <https://doi.org/10.3390/biomedicines12050981>
- Borghetti, G., von Lewinski, D., Eaton, D. M., Sourij, H., Houser, S. R., & Wallner, M. (2018). Diabetic cardiomyopathy: Current and future therapies. Beyond glycemic control. In *Frontiers in Physiology* (Vol. 9, Issue OCT). Frontiers Media S.A. <https://doi.org/10.3389/fphys.2018.01514>
- Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., Drazner, M. H., Michael Felker, G., Filippatos, G., Fiuzat, M., Fonarow, G. C., Gomez-Mesa, J. E., Heidenreich, P., Imamura, T., Jankowska, E. A., ... Zieroth, S. (2021). Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *European Journal of Heart Failure*, 23(3), 352–380. <https://doi.org/10.1002/ejhf.2115>

Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L. (2021). Ceramides and other sphingolipids as drivers of cardiovascular disease. *Nature Reviews Cardiology*, *18*(10), 701–711. <https://doi.org/10.1038/s41569-021-00536-1>

de Souza, R. R., Toebe, M., Mello, A. C., & Bittencourt, K. C. (2023). Sample size and Shapiro-Wilk test: An analysis for soybean grain yield. *European Journal of Agronomy*, *142*, 126666. <https://doi.org/https://doi.org/10.1016/j.eja.2022.126666>

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., McCoy, R. G., Mentz, R. J., & Piña, I. L. (2019). Type 2 diabetes mellitus and heart failure a scientific statement from the American Heart Association and the Heart Failure Society of America. In *Circulation* (Vol. 140, Issue 7, pp. E294–E324). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIR.0000000000000691>

el Hadj Othmane, T., el Hadj Othmane, O., & Nizar, H. (2025). Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review. *Cureus*, *17*(3), e81512. <https://doi.org/10.7759/cureus.81512>

Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE, P. (n.d.). *PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI*.

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>

Gallo, G., & Savoia, C. (2024). Hypertension and Heart Failure: From Pathophysiology to Treatment. In *International Journal of Molecular Sciences* (Vol. 25, Issue 12). Multidisciplinary Digital Publishing Institute (MDPI). <https://doi.org/10.3390/ijms25126661>

- Gerstein, H. C., Swedberg, K., Carlsson, J., McMurray, J. J. v, Michelson, E. L., Olofsson, B., Pfeffer, M. A., Yusuf, S., & Investigators, C. P. (2008). The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. *Archives of Internal Medicine*, *168*(15), 1699–1704. <https://doi.org/10.1001/archinte.168.15.1699>
- Ghasemi, A. G., & Zahediasl, S. Z. (n.d.). Normality Tests for Statistical Analysis: A Guide for Non-Statisticians. *International Journal of Endocrinology and Metabolism*, *10*(2), 486–489. <https://doi.org/10.5812/ijem.3505>
- Harada, T., & Obokata, M. (2020). Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies. *Heart Failure Clinics*, *16*(3), 357–368. <https://doi.org/https://doi.org/10.1016/j.hfc.2020.02.004>
- Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S., & Selby, J. v. (2001). *Glycemic Control and Heart Failure Among Adult Patients With Diabetes*. <http://www.circulationaha.org>
- Jia, G., DeMarco, V. G., & Sowers, J. R. (2016). Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. *Nature Reviews Endocrinology*, *12*(3), 144–153. <https://doi.org/10.1038/nrendo.2015.216>
- Khan, M. T. I., Khan, M. H., Tabassum, M., Hassan, M., Mahmud, S. T., & Naznen, F. (2022). Association of Admission Glucose Level with Arrhythmia and Heart Failure in Hyperglycemic Patients with Non-ST-Segment Elevation Myocardial Infarction. *International Journal of Human and Health Sciences (IJHHS)*, *6*(3), 292. <https://doi.org/10.31344/ijhhs.v6i3.461>
- Klaeboe, L. G., & Edvardsen, T. (2019). Echocardiographic assessment of left ventricular systolic function. In *Journal of Echocardiography* (Vol. 17, Issue 1, pp. 10–16). Springer Tokyo. <https://doi.org/10.1007/s12574-018-0405-5>
- Lechat, P., Brunhuber, K. W., Hofmann, R., Kuhn, P., Nesser, H. J., Slany, J., Weihs, W.,

- Wiedermann, C., Wimmer, H., Mieghem, W., Boland, J., Chaudron, J. M., Jordaens, L., Melchior, J. P., Aschermann, M., Bruthansl, J., Hradec, M., Kolbel, F., Semrad, B., & Jmouro, A. v. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *The Lancet*, 353.
- Lin, Y. T., Huang, W. L., Wu, H. P., Chang, M. P., & Chen, C. C. (2021). Association of mean and variability of hba1c with heart failure in patients with type 2 diabetes. *Journal of Clinical Medicine*, 10(7). <https://doi.org/10.3390/jcm10071401>
- McDonagh, T. A., Metra, M., Adamo, M., Baumbach, A., Böhm, M., Burri, H., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gardner, R. S., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., ... Koskinas, K. C. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. In *European Heart Journal* (Vol. 42, Issue 36, pp. 3599–3726). Oxford University Press. <https://doi.org/10.1093/eurheartj/ehab368>
- McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Celutkienė, J., Chioncel, O., Cleland, J. G. F., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., ... Zeppenfeld, K. (2023). 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, 44(37), 3627–3639. <https://doi.org/10.1093/eurheartj/ehad195>
- McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971). The Natural History of Congestive Heart Failure: The Framingham Study. *New England Journal of Medicine*, 285(26), 1441–1446. <https://doi.org/10.1056/NEJM197112232852601>
- Mishra, P., Pandey, C. M., Singh, U., Gupta, A., Sahu, C., & Keshri, A. (2019). Descriptive Statistics and Normality Tests for Statistical Data. *Annals of Cardiac Anaesthesia*, 22(1).

[https://journals.lww.com/aoca/fulltext/2019/22010/descriptive\\_statistics\\_and\\_normality\\_tests\\_for.11.aspx](https://journals.lww.com/aoca/fulltext/2019/22010/descriptive_statistics_and_normality_tests_for.11.aspx)

Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., Namba, Y., Yoshida, M., Sugiyama, H., & Ito, H. (2022). Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. In *International Journal of Molecular Sciences* (Vol. 23, Issue 7). MDPI. <https://doi.org/10.3390/ijms23073587>

Park, J. J. (2021). Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. In *Diabetes and Metabolism Journal* (Vol. 45, Issue 2, pp. 146–157). Korean Diabetes Association. <https://doi.org/10.4093/DMJ.2020.0282>

Rodriguez-Araujo, G., & Nakagami, H. (2018). Pathophysiology of cardiovascular disease in diabetes mellitus. In *Cardiovascular Endocrinology and Metabolism* (Vol. 7, Issue 1, pp. 4–9). Lippincott Williams and Wilkins. <https://doi.org/10.1097/XCE.0000000000000141>

Royston, J. P. (1982). An Extension of Shapiro and Wilk's W Test for Normality to Large Samples. *Journal of the Royal Statistical Society. Series C (Applied Statistics)*, 31(2), 115–124. <https://doi.org/10.2307/2347973>

Safiri, S., Karamzad, N., Kaufman, J. S., Bell, A. W., Nejadghaderi, S. A., Sullman, M. J. M., Moradi-Lakeh, M., Collins, G., & Kolahi, A. A. (2022). Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.838027>

Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2022). Global burden of heart failure: a comprehensive and updated review of epidemiology. In *Cardiovascular Research* (Vol. 118, Issue 17, pp. 3272–3287). Oxford University Press. <https://doi.org/10.1093/cvr/cvac013>

Solomon, S. D., McMurray, J. J. v, Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., ... Lefkowitz, M. P. (2019). Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*, *381*(17), 1609–1620. <https://doi.org/10.1056/NEJMoa1908655>

The SOLVD Investigators. (1992). Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. *New England Journal of Medicine*, *327*(10), 685–691. <https://doi.org/10.1056/NEJM199209033271003>

Wilkinson, M. J., Zadourian, A., & Taub, P. R. (2019). Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. In *American Journal of Cardiology* (Vol. 124, pp. S3–S11). Elsevier Inc. <https://doi.org/10.1016/j.amjcard.2019.10.024>

Yan, T., Zhu, S., Yin, X., Xie, C., Xue, J., Zhu, M., Weng, F., Zhu, S., Xiang, B., Zhou, X., Liu, G., Ming, Y., Zhu, K., Wang, C., & Guo, C. (2023). Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study. *Journal of the American Heart Association*, *12*(6). <https://doi.org/10.1161/JAHA.122.027852>

Yap, J., Tay, W. T., Teng, T. H. K., Anand, I., Richards, A. M., Ling, L. H., Macdonald, M. R., Chandramouli, C., Tromp, J., Siswanto, B. B., Zile, M., McMurray, J., & Lam, C. S. P. (2019). Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. *Journal of the American Heart Association*, *8*(17). <https://doi.org/10.1161/JAHA.119.013114>

Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J. v, Michelson, E. L., Olofsson, B., & Östergren, J. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *The Lancet*, *362*(9386), 777–781. [https://doi.org/10.1016/S0140-6736\(03\)14285-7](https://doi.org/10.1016/S0140-6736(03)14285-7)

Zhang, H., Qin, L., Sheng, C. S., Niu, Y., Gu, H., Lu, S., Yang, Z., Tian, J., & Su, Q.  
(2020). ASCVD risk stratification modifies the effect of HbA1c on cardiovascular  
events among patients with type 2 diabetes mellitus with basic to moderate risk.  
*BMJ Open Diabetes Research and Care*, 8(1). <https://doi.org/10.1136/bmjdr-2019-000810>